Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with sjögren’s syndrome

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 11, 2014, Pages 7079-7084

  McNamara, Nancy A ^a,b,c   Gallup, Marianne ^a   Porco, Travis C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dry eye; Ocular surface; PAX6; Sj gren s syndrome; Squamous metaplasia

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; PROLINE RICH PROTEIN; RHEUMATOID FACTOR; TRANSCRIPTION FACTOR PAX6; BIOLOGICAL MARKER; PAX5 PROTEIN, HUMAN; RNA; TRANSCRIPTION FACTOR PAX5;

ADULT; ARTICLE; BLEPHARITIS; CLINICAL ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRY EYE; EYE INFLAMMATION; FEMALE; HUMAN; HUMAN TISSUE; IMPRESSION CYTOLOGY; KERATINIZATION; LABIAL SALIVARY GLAND FOCUS SCORE; MALE; MEIBOMITIS; MIDDLE AGED; OCULAR STAINING SCORE; OCULAR SURFACE DISEASE; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCHIRMER TEST; SCORING SYSTEM; SJOEGREN SYNDROME; TEAR BREAKUP TIME; VISUAL SYSTEM PARAMETERS; BIOSYNTHESIS; COMPARATIVE STUDY; GENETICS; KERATOCONJUNCTIVITIS SICCA; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; BIOLOGICAL MARKERS; CONJUNCTIVA; DOWN-REGULATION; FEMALE; HUMANS; KERATOCONJUNCTIVITIS SICCA; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA; SJOGREN'S SYNDROME;

EID: 84910047122     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14828     Document Type: Article

References (31)

1. Li W, Hayashida Y, Chen YT, et al. Air exposure induced squamous metaplasia of human limbal epithelium. Invest Ophthalmol Vis Sci. 2008;49:154-162.
2. Li W, Chen YT, Hayashida Y, et al. Down-regulation of Pax6 is associated with abnormal differentiation of corneal epithelial cells in severe ocular surface diseases. J Pathol. 2008;214:114- 122.
3. Sun TT. Altered phenotype of cultured urothelial and other stratified epithelial cells: implications for wound healing. Am J Physiol Renal Physiol. 2006;291:F9-F21.
4. Tseng SC. Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology. 1985;92:728-733.
5. Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol. 1984;102:1049- 1051.
6. Koroma BM, Yang JM, Sundin OH. The Pax-6 homeobox gene is expressed throughout the corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci. 1997;38:108-120.
7. Davis J, Duncan MK, Robison WG Jr, Piatigorsky J. Requirement for Pax6 in corneal morphogenesis: a role in adhesion. J Cell Sci. 2003;116:2157-2167.
8. Ramaesh T, Collinson JM, Ramaesh K, Kaufman MH, West JD, Dhillon B. Corneal abnormalities in Pax6þ/_ small eye mice mimic human aniridia-related keratopathy. Invest Ophthalmol Vis Sci. 2003;44:1871-1878.
9. Dora N, Ou J, Kucerova R, Parisi I, West JD, Collinson JM. PAX6 dosage effects on corneal development, growth, and wound healing. Dev Dyn. 2008;237:1295-1306.
10. Davis J, Piatigorsky J. Overexpression of Pax6 in mouse cornea directly alters corneal epithelial cells: changes in immune function, vascularization, and differentiation. Invest Ophthalmol Vis Sci. 2011;52:4158-4168.
11. Chen YT, Lazarev S, Bahrami AF, et al. Interleukin-1 receptor mediates the interplay between CD4(þ) T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren's syndrome. Lab Invest. 2012;92:556-570.
12. Chen YT, Li S, Nikulina K, Porco T, Gallup M, McNamara N. Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye. Mol Vis. 2009;15: 563-576.
13. Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome. Am J Pathol. 2010;177:1333-1343.
14. DeVoss J, Hou Y, Johannes K, et al. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med. 2006;203:2727-2735.
15. DeVoss JJ, LeClair NP, Hou Y, et al. An autoimmune response to odorant binding protein 1a is associated with dry eye in the aire-deficient mouse. J Immunol. 2010;184:4236-4246.
16. Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol. 2010;149:405-415.
17. Daniels TE. Salivary histopathology in diagnosis of Sjogren's syndrome. Scand J Rheumatol Suppl. 1986;61:36-43.
18. Daniels TE, Cox D, Shiboski CH, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1,726 registry participants. Arthritis Rheum. 2011;63:2021-2030.
19. Shiboski S, Shiboski C, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken). 2012;64:475-487.
20. Bian F, Qi H, Ma P, et al. An immunoprotective privilege of corneal epithelial stem cells against Th17 inflammatory stress by producing glial cell-derived neurotrophic factor. Stem Cells. 2010;28:2172-2181.
21. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48:2561-2569.
22. Li S, Nikulina K, DeVoss J, et al. Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease. Invest Ophthalmol Vis Sci. 2008;49:34-41.
23. Collinson JM, Hill RE, West JD. Different roles for Pax6 in the optic vesicle and facial epithelium mediate early morphogenesis of the murine eye. Development. 2000;127:945-956.
24. Grindley JC, Davidson DR, Hill RE. The role of Pax-6 in eye and nasal development. Development. 1995;121:1433-1442.
25. Chen YT, Chen FY, Vijmasi T, Stephens DN, Gallup M, McNamara NA. Pax6 downregulation mediates abnormal lineage commitment of the ocular surface epithelium in aqueous-deficient dry eye disease. PLoS One. 2013;8:e77286.
26. McDermott AM, Perez V, Huang AJ, et al. Pathways of corneal and ocular surface inflammation: a perspective from the Cullen symposium. Ocul Surf. 2005;3:S131-S138.
27. Vijmasi T, Chen FY, Chen YT, Gallup M, McNamara N. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis. 2013;19:1957-1965.
28. Li S, Gallup M, Chen YT, McNamara N. Molecular mechanism of proinflammatory cytokine-mediated squamous metaplasia in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2010;51:2466-2475.
29. Li T, Lu Z, Lu L. Pax6 regulation in retinal cells by CCCTC binding factor. Invest Ophthalmol Vis Sci. 2006;47:5218- 5226.
30. Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131:715- 723.
31. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;154:63-71.